<DOC>
	<DOCNO>NCT02587403</DOCNO>
	<brief_summary>The objective study compare effectiveness Fortiva Porcine Dermis versus Strattice Reconstructive Tissue Matrix underlay reinforcement complex ventral hernia repair assess post-operative complication rate , long term hernia recurrence rate .</brief_summary>
	<brief_title>A Comparison Fortiva Strattice Tissue Matrices Complex , Ventral Hernia Repair</brief_title>
	<detailed_description>This randomize , prospective , double-blinded study evaluate efficacy Fortiva Porcine Dermis versus Strattice Reconstructive Tissue Matrix 120 patient large complex abdominal wall ventral hernia undergo single stage repair . The patient blind treatment well independent qualify evaluator confirm evidence reoccurrence . This post-market study compare two FDA clear biologic hernia material . Fortiva™ porcine dermis , process RTI Surgical , Inc. , non-cross link porcine dermis compare Strattice™ Reconstructive Tissue Matrix Life Cell , non-cross link porcine dermis reinforcement single stage open reconstruction abdominal wall defect . The primary outcome hernia recurrence 1 year . Outcomes evaluate 6 week , 3 month , 6 month 12 month 24 month .</detailed_description>
	<mesh_term>Hernia</mesh_term>
	<mesh_term>Hernia , Ventral</mesh_term>
	<criteria>18 year age great Have BMI &lt; equal 40 Have preoperative estimate hernia defect 200 cm2 OR multiple hernia defect whose combined area ≥ estimate 200 cm2 . Patients whose defect NOT meet exceed 200 cm2 intraoperatively withdraw study consider intraoperative screen failure Have contraindication test material ( ) Have life expectancy great 1 year opinion Investigator Able provide inform consent Able willing return schedule study visit 2 year postoperatively ( follow research relate surgery ) &lt; 18 year age Subject determined American Society Anesthesiologists ' ( ASA ) physical class 4 , 5 , 6 Have BMI &gt; 40 Have hernia estimate &lt; 200 cm2 Have abdominal loss domain operation would impractical would adversely affect respiratory cardiovascular function unacceptable degree opinion investigator Inability close fascia primarily without abdominal wall mobilization component separation Participation investigational drug device study would impact safety scientific integrity study ( opinion Investigator approval Sponsor ) within past 6 week prior enrollment trial Have active necrotizing fasciitis know active local systemic infection Have know collagen metabolism disorder medical condition could interfere normal tissue heal process determine Investigator Have know active malignancy present and/or chemotherapy 12 week prior screen plan chemotherapy within 12 week enrollment exception BCC SCC Have know moderate severe cirrhosis opinion Investigator would impact outcome trial Have life expectancy le 1 year Be unable participate inform consent process Be unable unwilling return schedule study visit 2 year postoperative assessment period Received high dose steroid ( &gt; /=100mg prednisone ) within past 6 week Known tobacco use within past 6 week positive serum cotinine test time admission Uncontrolled diabetes ( i.e . know HbA1C value &gt; 7 % within last 6 week ) History drug addiction ( recreational drug , prescription drug alcohol ) Investigator 's opinion may interfere protocol assessment and/or subject 's ability complete require follow Pregnancy and/or breastfeed Enterocutaneous fistula Ventral hernia repair involve active infection Inability obtain primary fascial closure ( Intraoperatively ) Planned use external VAC dressing intraoperatively</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>